Data from SREBP1c and PPARγ could suggest a potential increased phagocytic condition in animals administered SETIs, which may interpret the results in a way to obtain better control of the lipid accumulation influencing innate immune activation to ameliorate HCC severity under an HFD. The gene discussed is SREBF1; the disease is hepatocellular carcinoma.